IL160620A0 - Combinations comprising cox-2 inhibitors and aspirin - Google Patents

Combinations comprising cox-2 inhibitors and aspirin

Info

Publication number
IL160620A0
IL160620A0 IL16062002A IL16062002A IL160620A0 IL 160620 A0 IL160620 A0 IL 160620A0 IL 16062002 A IL16062002 A IL 16062002A IL 16062002 A IL16062002 A IL 16062002A IL 160620 A0 IL160620 A0 IL 160620A0
Authority
IL
Israel
Prior art keywords
aspirin
cox
inhibitors
combinations
Prior art date
Application number
IL16062002A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL160620A0 publication Critical patent/IL160620A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL16062002A 2001-10-11 2002-10-10 Combinations comprising cox-2 inhibitors and aspirin IL160620A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124459.9A GB0124459D0 (en) 2001-10-11 2001-10-11 Organic compounds
PCT/EP2002/011380 WO2003033001A1 (fr) 2001-10-11 2002-10-10 Combinaisons contenant un inhibiteur de cox-2 et de l'aspirine

Publications (1)

Publication Number Publication Date
IL160620A0 true IL160620A0 (en) 2004-07-25

Family

ID=9923664

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16062002A IL160620A0 (en) 2001-10-11 2002-10-10 Combinations comprising cox-2 inhibitors and aspirin

Country Status (19)

Country Link
US (2) US20040235802A1 (fr)
EP (1) EP1435968A1 (fr)
JP (1) JP2005505606A (fr)
KR (1) KR20040044891A (fr)
CN (1) CN1625405A (fr)
AU (1) AU2006249254A1 (fr)
BR (1) BR0213181A (fr)
CA (1) CA2458981A1 (fr)
CO (1) CO5570661A2 (fr)
GB (1) GB0124459D0 (fr)
HU (1) HUP0401854A2 (fr)
IL (1) IL160620A0 (fr)
MX (1) MXPA04003365A (fr)
NO (1) NO20041432L (fr)
NZ (1) NZ532158A (fr)
PL (1) PL369005A1 (fr)
RU (1) RU2004114560A (fr)
WO (1) WO2003033001A1 (fr)
ZA (1) ZA200401302B (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040122011A1 (en) * 1998-12-23 2004-06-24 Pharmacia Corporation Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
US7338971B2 (en) 2001-08-30 2008-03-04 El-Naggar Mawaheb M Treatment of inflammatory, cancer, and thrombosis disorders
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
EP1539134A4 (fr) 2002-06-11 2007-04-11 Nitromed Inc Inhibiteurs selectifs de cyclooxigenase-2 nitroses et/ou nitrosyles, compositions et methodes d'utilisation
AU2005206227A1 (en) * 2004-01-27 2005-08-04 Merck Frosst Company Combination therapy for treating cyclooxygenase-2 mediated diseases or conditions in patients at risk of thrombotic cardiovascular events
ATE480229T1 (de) * 2005-05-24 2010-09-15 Flamel Tech Sa Orale pharmazeutische zusammensetzung zur behandlung einer cox-2-vermittelten erkrankung
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
EP1919288A4 (fr) * 2005-07-18 2009-12-16 Horizon Therapeutics Inc Medicaments contenant famotidine et ibuprofene, et administration desdits medicaments
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
WO2008027963A2 (fr) * 2006-08-31 2008-03-06 Horizon Therapeutics, Inc. Formulations à dose unique d'ains avec antagonistes du récepteur de h2, et procédés d'utilisation
US9757529B2 (en) * 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN104173359B (zh) * 2014-09-05 2017-05-03 罗国安 一种降低罗非考昔副作用的消炎镇痛复方药物及其应用
WO2018167447A1 (fr) * 2017-03-14 2018-09-20 University Of Sheffield Aspirine à faible dose (1-50 mg) conjointement avec des antiagrégants plaquettaires de type ticagrelor d'anticoagulants
US10272107B2 (en) * 2017-09-05 2019-04-30 Kenneth O. Russell Method for treating inflammatory brain disorders and traumatic brain injury
US10586872B2 (en) * 2018-07-03 2020-03-10 International Business Machines Corporation Formation of wrap-around-contact to reduce contact resistivity

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743596A (en) * 1987-06-16 1988-05-10 Lapin Alfred R Anti-arthritic preparation
CO4960662A1 (es) * 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US6136804A (en) * 1998-03-13 2000-10-24 Merck & Co., Inc. Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions
KR100664479B1 (ko) * 1999-12-08 2007-01-04 파마시아 코포레이션 발데콕시브 조성물
GB0002336D0 (en) * 2000-02-01 2000-03-22 Glaxo Group Ltd Medicaments
US8680081B2 (en) * 2000-08-29 2014-03-25 Peter Van Patten Prophylactic treatment of migraine

Also Published As

Publication number Publication date
US20040235802A1 (en) 2004-11-25
CA2458981A1 (fr) 2003-04-24
EP1435968A1 (fr) 2004-07-14
WO2003033001A1 (fr) 2003-04-24
JP2005505606A (ja) 2005-02-24
GB0124459D0 (en) 2001-12-05
NO20041432L (no) 2004-06-28
NO20041432D0 (no) 2004-04-05
NZ532158A (en) 2006-04-28
KR20040044891A (ko) 2004-05-31
HUP0401854A2 (hu) 2004-12-28
CN1625405A (zh) 2005-06-08
BR0213181A (pt) 2004-08-31
CO5570661A2 (es) 2005-10-31
ZA200401302B (en) 2005-01-04
RU2004114560A (ru) 2005-05-20
PL369005A1 (en) 2005-04-18
US20080027032A1 (en) 2008-01-31
AU2006249254A1 (en) 2007-01-04
MXPA04003365A (es) 2004-07-23

Similar Documents

Publication Publication Date Title
HK1061851A1 (en) Gyrase inhibitors and uses thereof
SI1251848T1 (en) Gyrase inhibitors and uses thereof
EP1423120A4 (fr) 2h-phtalazine-1-ones et procedes d'utilisation de celles-ci
PL374598A1 (en) Caspase inhibitors and uses thereof
IL172752A0 (en) Cox-2 and faah inhibitors
IL160620A0 (en) Combinations comprising cox-2 inhibitors and aspirin
EP1435989A4 (fr) Inhibiteurs et ligands de ptp1b
AU2002361861A8 (en) Selective 11beta-hsd inhibitors and methods for use thereof
AU4217201A (en) Tri-aryl-substituted-ethane pde4 inhibitors
GB0114014D0 (en) Compostion and use
EP1434772A4 (fr) Composes et procedes
GB2376073B (en) Fluid-gauging systems and methods
AU2002359694A8 (en) Compounds and methods
AU2001232809A1 (en) Gyrase inhibitors and uses thereof
GB2382598B (en) Construction and elongate members therefor
ZA200306331B (en) Piperazinylcarbonylquinolines and isoquinolines
EP1379240A4 (fr) Composes et methodes
EP1367123A4 (fr) Neurotonine et utilisation
GB0220776D0 (en) FOXP2 and uses thereof
AU2003267790A8 (en) Lipase inhibitors and uses thereof
GB0109278D0 (en) Enzyme inhibitors
GB0106063D0 (en) Libraries and their use
AU2002363187A1 (en) Heterocyclo-alkylsulfonyl pyrazoles and their use as cox-2 inhibitors
AU2002223649A1 (en) Vegh inhibitors and their use
AU2002259301A1 (en) Caspase inhibitors and uses thereof